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Abstract: Exposure to hydrochloric acid (HCl) leads acutely to asthma-like symptoms, acute respira-
tory distress syndrome (ARDS), including compromised alveolo-capillary barrier, and respiratory
failure. To better understand the direct effects of HCl on pulmonary endothelial function, we studied
the characteristics of HCl-induced endothelial barrier dysfunction in primary cultures of human lung
microvascular endothelial cells (HLMVEC), defined the involved molecular pathways, and tested
the potentially beneficial effects of Heat Shock Protein 90 (HSP90) inhibitors. HCl impaired barrier
function in a time- and concentration-dependent manner and was associated with activation of
Protein Kinase B (AKT), Ras homolog family member A (RhoA) and myosin light chain 2 (MLC2), as
well as loss of plasmalemmal VE-cadherin, rearrangement of cortical actin, and appearance of inter-
endothelial gaps. Pre-treatment or post-treatment of HLMVEC with AUY-922, a third-generation
HSP90 inhibitor, prevented and restored HCl-induced endothelial barrier dysfunction. AUY-922
increased the expression of HSP70 and inhibited the activation (phosphorylation) of extracellular-
signal regulated kinase (ERK) and AKT. AUY-922 also prevented the HCl-induced activation of RhoA
and MLC2 and the internalization of plasmalemmal VE-cadherin. We conclude that, by increasing
the expression of cytoprotective proteins, interfering with actomyosin contractility, and enhancing
the expression of junction proteins, inhibition of HSP90 may represent a useful approach for the
management of HCl-induced endothelial dysfunction and acute lung injury.
Keywords: acidosis; hydrochloric acid; HCl; endothelial dysfunction; heat shock protein; HSP90
inhibition; AUY-922; acute lung injury
1. Introduction
Exposure to hydrochloric gas represents a threat to public health. Every year,
~2.5 million metric tons of hydrochloric gas are produced worldwide and employed
widely in oil and gas drilling facilities, science laboratories, swimming pools, and ille-
gal drug manufacturing. Hydrochloric acid inhalation provokes a wide range of respi-
ratory symptoms which are directly related to its concentration and duration of expo-
sure [1]. Patients develop cough, shortness of breath, pulmonary edema, and pneumonitis,
which can culminate in acute distress respiratory syndrome (ARDS), obstructive respira-
tory failure and, at higher doses, even death [2]. Usually, respiratory symptoms last for
3–7 days, but several cases of persistent asthma-like conditions, pleural thickening, and
pulmonary fibrosis have been described, which can occur even after a single exposure to
this dangerous chemical [3–5]. This has been replicated in a murine model of hydrochloric
acid-instilled mice, which after 30 days culminated in loss of lung alveolar architecture,
collagen deposition and pulmonary fibrosis [6,7]. Due to its high solubility, hydrochloric
gas dissolves in saliva and mucus of the airways, creating hydrochloric acid (HCl). HCl
Cells 2021, 10, 1489. https://doi.org/10.3390/cells10061489 https://www.mdpi.com/journal/cells
Cells 2021, 10, 1489 2 of 12
is a strong acid, capable of easily donating H+ ions, provoking direct chemical burns to
cells and tissue, causing tissue destruction and alveolar hemorrhage [8], and eliciting
a strong inflammatory response. As we have previously shown, HCl increases the number
of leucocytes (WBC) in the bronchoalveolar lavage fluid (BALF), mostly monocytes and
lymphocytes, and stimulates high levels of interleukins (IL-2, IL-10, IL-6, MCP-1, and
TGF-β) [6]. BALF is further characterized by increased proteinosis, reflecting acute damage
to the alveolar–endothelial barrier. The increased permeability of endothelial cells, which
allows the passage of inflammatory cells and proteins, is believed to be the initial step in
the inflammatory response of the lung [9]. There are no antidotes against HCl-induced lung
injury as yet, but certain candidates have emerged. Among these, the inhibition of heat
shock protein 90 (HSP90), a highly expressed and conserved chaperone, has been proposed
as a potential therapeutic target in models of lipopolysaccharide (LPS)-, TGF-β-, thrombin-,
or VEGF- induced endothelial barrier dysfunction [10,11]. Under physiologic conditions,
HSP90 is responsible for the correct folding of more than 400 “client” proteins [12]. Many
of these client proteins represent key steps in the pathogenesis of several diseases, so that
inhibition of HSP90 represents an exciting area of research in the management of lung in-
jury [13,14], cancer [15], and neurodegenerative disorders [16,17]. In addition, HSP90 exerts
a crucial role in the development of inflammation, and HSP90 inhibitors have been shown
to modulate the inflammatory cascade and the transcription of acute phase proteins [18].
Therefore, we hypothesized that inhibition of HSP90, by AUY-922 a third generation HSP90
inhibitor, employed either as pre-treatment or post-treatment, could represent an important
therapeutic intervention against HCl-induced endothelial barrier dysfunction.
2. Materials and Methods
2.1. Reagents
Hydrochloric acid (ACS grade), red protein G affinity beads, RIPA buffer, and protease
inhibitor cocktail were purchased from Sigma-Aldrich Corporation (St. Louis, MO, USA).
AUY-922 was obtained from Selleck Chemicals (Houston, TX, USA). The BCA Protein
assay kit was from Pierce Co. (Rockford, IL, USA), and Western blot membranes from
GE Healthcare (Chicago, IL, USA). All antibodies used in Western blots and immuno-
precipitation have published immunospecificity data available online. Rabbit anti-AKT
(9272S), anti-RhoA (67B9), anti-myosin light chain 2 (3672), anti-phospho-MLC2 (3674S),
and anti-HSP70 antibodies were purchased from Cell Signaling Technology (Danvers,
MA, USA). Mouse monoclonal anti-β-actin was purchased from Sigma-Aldrich Corpo-
ration, and secondary IRDye 800CW goat anti-rabbit (926-32211) and IRDye 680RD goat
anti-mouse (926-68070) from LI-COR Biosciences (Lincoln, NE, USA). For antibodies used
in immunoprecipitation, mouse anti-phosphotyrosine was from Invitrogen, and mouse
anti-HSP90 from BD Transduction Laboratories (Franklin Lakes, NJ, USA). For SDS-PAGE:
Protogel (30% acrylamide mix) and TEMED were from National Diagnostics (Atlanta, GA,
USA), Tris-HCl buffer from Teknova (Hollister, CA, USA), 10% SDS, Trypan Blue 0.4%
solution, and ammonium persulfate from Thermo Fisher Scientific (Waltham, MA, USA),
and protein dual color standards and tricine sample buffer from Bio-Rad Laboratories.
2.2. Cell Culture and Cell Viability
In-house harvested human lung microvascular endothelial cells (HLMVEC) were
maintained in M199 media supplemented with 20% FBS and antibiotics/antimycotics as
described previously [19]. To assess possible changes in viability, HLMVEC were incubated
with different concentrations of AUY-922 (1, 2 or 10 µM). After 24 h, cells were resuspended,
Trypan Blue-treated, and counted by hemocytometer. Experiments were run in triplicates,
and data are reported as percent of control (vehicle).
2.3. Endothelial Barrier Function
HLMVEC were seeded on electrode arrays (8W10E+), and endothelial barrier integrity
was estimated by the electric substrate impedance sensing (ECIS) technique, using an ECIS
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model 1600R ζθ instrument (Applied BioPhysics). Experiments were conducted when
a stable resistance was maintained above 800 Ω, as we have previously published [20].
Experiments were performed in triplicates and repeated at least three times. Resistance
values were collected and normalized to each well’s value at t = 0. Data are presented as
mean values (±SEM). Results were considered significant when p < 0.05 with one-way
ANOVA and Tukey’s post-test.
2.4. Protein Isolation and Western Blots
HLMVEC were cultured in 100 mm dishes until 90–95% confluency. For pre-treatment,
cells were incubated with either 2 µM AUY-922 or vehicle (saline) and after 24 h were
exposed to HCl (0.01 N) for 1 h before protein isolation. For post-treatment, confluent dishes
were instilled with HCl (0.01 N), and after 5 min treated with either AUY-922 or vehicle
(saline) for 3.5 h. To stop the experiment, dishes were placed on ice and washed 3× with
ice-cold PBS. PBS was removed, and ice-cold lysis buffer was added (RIPA with protease
inhibitor cocktail 1:100). Cells were scraped and the cell suspension was transferred to
a microcentrifuge tube. Tubes were placed at 4 ◦C for 30 min under continuous agitation.
Protein concentration was estimated by the BCA protein assay. Equal volumes of tricine
buffer with 2% 2-mercaptoethanol were added to samples containing equal amounts of
protein. Proteins were denaturated by 10 min boiling at 100 ◦C. Protein lysates were then
subjected to SDS-PAGE in 8%, 10%, and 12% sodium dodecyl sulfate Tris-HCl gels. Proteins
were transferred onto nitrocellulose membranes and blocked for 1 h at room temperature
in 5% non-fat dry milk in tris-buffered saline containing 0.1% Tween 20. Membranes were
incubated overnight at 4 ◦C with specific antibodies, washed 4×, and incubated for 1 h
at room temperature with appropriate peroxidase-conjugated secondary antibody. Bands
were detected by digital fluorescence imaging (LI-COR Odyssey CLx). Densitometric
evaluation of the bands was made using ImageJ software (National Institutes of Health,
Bethesda, MD, USA). B-actin was used as a loading control.
2.5. Immunocytochemistry
Round coverslips (Thermo Fisher Scientific) were placed in 12-well plates, soaked
in 70% ethanol for 15 min, and dried under the hood. The cover glasses inside the wells
were covered with 1 mL 0.2% gelatin and incubated 30 min at 37 ◦C. Excess gelatin was
aspirated, and 500 µL of cell suspension containing 6 × 105 HLMVEC was placed on top.
Coverslips with at least 90% confluent HLMVEC were fixed in 4% paraformaldehyde in
PBS for 10 min, washed 3×, permeabilized with 0.1% Triton-X 100 in TBS for 10 min, triple
washed in PBS, and blocked with 5% BSA in 0.1% TWEEN overnight at 4 ◦C. The next
day, coverslips were moved to a wet camera and incubated with VE-cadherin antibody
(Abcam, 1:50 dilution) in blocking buffer at 4 ◦C for 24 h. After 5× washes in PBS, cells
were incubated with Alexa Fluor 488 goat anti-rabbit secondary antibody (Thermo Fisher
Scientific, dilution 1:500) in the dark at RT for 1 h and then washed 5×. F-Actin was stained
using Texas Red—X phalloidin (Life Technologies, diluted 1:300). At the counterstaining
stage, cells were incubated with 300 µM DAPI for 5 min in the dark. One drop of mounting
media (ProLong Plus, Thermo Fisher Scientific) was added onto pre-cleaned microscope
slides (Superfrost Plus, Thermo Fisher Scientific), placed over the top of the coverslips
facing down, extra PBS was removed from the edges, and final slides were placed in the
dark at RT for overnight drying. Confocal analysis was performed with an Olympics
Fluoview FV10i microscope, and pictures were analyzed with ImageJ.
2.6. Statistical Analysis
Statistical significance of differences among groups was determined by the one-way
analysis of variance (ANOVA) followed by the Bonferroni or Tukey post hoc tests using
GraphPad Prism Software (GraphPad Software, San Diego, CA, USA). Differences among
groups were considered significant at p < 0.05.
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3. Results
3.1. HCl Elicits a Concentration-Dependent Decrease in TER
Increasing HCl concentrations linearly decreased pH in Dulbecco Modified Eagle
Medium (DMEM pH 7.64), the medium used in human lung microvascular endothelial
cells (HLMVEC) (Figure 1A). Furthermore, increasing concentrations of HCl decreased
trans-endothelial resistance (TER) of HLMVEC monolayers in a concentration-dependent
manner (Figure 1B).
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Figure 1. Hydrochloric acid (HCl) elicits a concentration-dependent decrease in pH (A) and trans-
endothelial resistance (TER); (B)). Line in (A) represents linear regression analysis (***: p < 0.001;
Pearson R2 coefficient 0.94). The maximal decrease in TER in (B) was plotted as a percentage of
the ba al resistance in the absence of HCl (n = 3, means ± SEM; ***: p < 0.001, one-way NOVA
with Tuckey’s).
3.2. Pre-Treatment with the HSP90 Inhibitor, AUY-922, Protects HLMVEC from HCl-Induced
Endothelial Barrier Dysfunction
HLMVEC were seeded on electrode arrays (8W10E+) till confluent. The HSP90 in-
hibitor, AUY-922, was added to a final conc ntration of 2 µM, 24 h prior to the addition
of HCl (0.01 N). The HCl dose as chosen from results shown in Figure 1B, as it reduces
TER by approximately 40%. HCl produced an immediate, time-dependent decrease in
TER, which was significantly reduced in cells pre-treated with AUY-922 (Figure 2A). To
make sure that the protective effect of AU-922 was not due to buffering and restoration
of normal pH, we measured pH values over a range of HCl concentrations, in the pres-
en e and absence of 2 µM AUY-922. There as no effect of the HSP90 inhibitor on pH
(Figure 2B). Furthermore, 24 h incubation with 1 or 2 µM AUY-922 did not affect cell
viability (Figure 2C).
3.3. Pre-Treatmen with AUY-922 Induces Cytoprotection
To explore mecha isms potentially responsible for the barrier protective effects of
HSP90 inhibition, we analyzed pathways involved with cell survival, cytoskeletal rear-
rangements, and tight junction expression. The inhibition of HSP90 for 24 h resulted in the
overexpression of HSP70, a well-known cytoprotective molecule. This effect was accom-
panied by the simultaneous inhibition of the phosphorylated (activated) form of HSP90
(p-HSP90), while no changes were observed in the levels of total HSP90 (Figure 3A–C).
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3.4. Pre-Treatment with AUY-922 Prevents the HCl-Induced AKT Phosphorylation
Protein kinase B (AKT) is critically involved in the integrity of the endothelial barrier.
Pre-treatment with 2 µM AUY-922 for 24 h completely inhibited AKT phosphorylation,
which was increased by HCl (Figure 4).
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3.5. Pre-Treatment with AUY-922 Modulates the Activation of Cytoskeletal 
Proteins and the Expression of Tight Junction Proteins 
Figure 4. The HSP90 inhibitor, AUY-922, prevents the HCl-induced AKT phosphorylation. HLMVEC
grown in 100 mm cultured dishes, were pre-treated for 24 h with 2 µM AUY-922 and then exposed
to 0.01 N HCl. One hour later, cells were lysed, and samples were prepared for protein analysis by
Western Blotting. Means ± SE ; n = 3; **: p <0.01; ***: p < 0.001 with one-way ANOVA nd Tukey’s.
3.5. Pre-Treatment with AUY-922 Modulates the Activation of Cytoskeletal Proteins and the
Expression of Tight Junction Proteins
The HCl-induced endothelial barrier dysfunction may be consequent to rearrange-
ments in the expression of cytoskeletal proteins and tight junction proteins. Pre-treatment
with the HSP90 inhibitor AUY-922 for 24 h prevented the HCl-induced activation of Ras
homolog family member A (RhoA), reduced the phosphorylation of myosin light chain
2 (MLC2), and increased the expression of VE-cadherin (Figure 5A–C).
3.6. Pre-Treatment of HLMVEC with AUY-922 for 24 h Prevents the HCl-Induced Loss of
Plasmalemmal VE-Cadherin
HLMVEC were seeded onto sterile, 0.2% gel-coated glass coverslips. When confluent,
they were pre-treated for 24 h with either PBS (control) or 2 µM AUY-922, before instillation
of 0.01 N HCl or vehicle. One hour later, the cells were fixed, permeabilized, blocked,
and incubated with VE-cadherin or F-actin antibody and counterstaining antibodies. HCl
created gaps among confluent cells, altered the cellular shape, and reduced the cortical
expression of VE-cadherin and F-actin. Pre-treatment with AUY-922 protected HLMVEC
from HCl-mediated damage, preserving VE-cadherin expression and concentrating F-
actin in the perinuclear areas (Figure 6A). Quantification of cortical VE-cadherin staining
further demonstrated that AUY-922 prevented HCl-induced loss of VE-cadherin staining
(Figure 6B).
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and Tukey’s.
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recovery in trans-endothelial resistance compared to cells instilled with HCL and treated
with vehicle (Figure 7).
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Figure 7. Post-treatment with the HSP90 inhibitor, AUY-922, repairs HCl-induced HLMVEC barrier
dysfunction. HLMVEC w re seeded on 8W10E+ arrays; when confluent (R > 800 Ω), 0.01 N HCl
(final concentration) was added (black arrow). At the nadir of the observed TER values, 2 µM (final
concentration) AUY-922 (grey arrow) or vehicle was added. TER was recorded continuously with an
interval time of 10 s and normalized to time = 0 h. Post-treatment with AUY-922 completely restored
endothelial barrier function. Means ± SEM; n = 3. ***: p < 0.001 between HCl and HCl + AUY groups,
one-way ANOVA with Bonferroni’s post-test.
3.8. Post-Treatment with AUY-922 Inhibited the Activation of AKT and ERK
HLMVEC were seeded in 100 mm dishes until confluent. Five minutes after addition
of 0.01 N HCl, AUY-922 (2 µM) was added; three hours later, dishes were put on ice,
cells lysed, and proteins analyzed. HCl activated (phosphorylated) both ERK and AKT;
post-treatment with AUY-922 completely inhibited both ERK and AKT phosphorylation
(Figure 8A, B).
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4. Discussion
Exposure to HCl provokes acute lung injury, which, depending on duration of expo-
sure and HCl concentration, could prove lethal. HCl acute toxicity is mediated by a direct
chemical burn, followed by leucocyte infiltration and activation of various proinflamma-
tory cytokines [6]. Alveolar hemorrhage, increased lung proteinosis, and cell infiltrates into
the BALF are common features as a result of damage to the endothelial–alveolar barrier [10].
If the endothelial injury persists, fluids move to the alveolar surface and impede oxygen
exchange, provoking acute respiratory distress syndrome (ARDS). Thus, targeting endothe-
lial cell dysfunction is an intriguing approach to acute lung injury. We investigated the
characteristics of HCl-mediated endothelial injury through continuous, real-time analysis of
changes in trans-endothelial electrical resistance (TER). TER reflects the level of endothelial
cell integrity and thus the function of the endothelial barrier. When toxins, chemicals, or
drugs damage the endothelial barrier, gaps occur between cells and the passage of proteins,
and liquid is facilitated. Exposure of HLMVEC to HCl led to a fast, concentration-dependent
perturbation of endothelial barrier function (Figures 1 and 2). As a strong acid, HCl is ca-
pable of reducing the pH of the media and of provoking cell injury. A pH reduction to
6.7 was enough to provoke changes in TER of 40%. However, inhibition of HSP90, ob-
tained by incubating cells with AUY-922 before HCl instillation (pre-treatment), resulted
in decreased damage to endothelial cells and preserved the function of the monolayer,
without affecting pH (Figure 2). These protective effects were also visible when AUY-922 was
employed after HCl exposure (post-treatment) and achieved complete recovery of endothelial
barrier function (Figure 7). To study the therapeutic effects of AUY-922 on the endothelium, we
analyzed two well-known HSP90 client proteins that would be affected by drugs that act on
HSP90’s chaperone function. Protein kinase B (AKT) and extracellular-signal regulated kinase
(ERK) were activated by HCl-induced injury, but this activation was completely blocked by
AUY-922 when employed either as pre-treatment or post-treatment (Figures 4 and 8). Both
kinases are involved in endothelial cell function. AKT modulates apoptotic pathways
and its signaling regulates angiogenesis via the PI3/AKT/mTOR pathway [21]. AKT
phosphorylation, in addition, regulates nitric oxide (NO) synthase (eNOS) activity and
cell proliferation and has been related to endothelial dysfunction observed in models of
hypertension [22]. ERK is involved in multiple signaling pathways and has been shown to
regulate vascular proliferation in response to insults [23].
TER data suggest that distinct cellular rearrangements occur when the monolayer
is exposed to HCl, alone or in the presence of AUY-922. These changes were reflected in
the activation of RhoA by HCl and the therapeutic modulation of RhoA and pMLC2 by
the HSP90 inhibitor (Figure 5). AUY-922 was also able to promote increased expression
of VE-cadherin (Figure 5) and prevent F-actin reorganization induced by HCl (Figure
6). HSP90 inhibitors preferentially target the activated—Tyr phosphorylated—form of
HSP90 and also induce overexpression of HSP70 (Figure 3). This is part of the heat shock
factor-1 (HSF-1) mediated response produced by HSP90 inhibition, and it is considered a
cytoprotective mechanism [24].
The inhibition of HSP90 by other HSP90 inhibitors, 17-AAG and 17-DMAG, has
been shown to be beneficial in an in vitro model of LPS-induced endothelial injury [10].
HSP90 inhibitors modulate endothelial inflammation via multiple mechanisms, including
the inhibition of the IKBα promoter [25] as well as their actions on Sirtuin 2 [26]. These
anti-inflammatory effects, together with the modulation of RhoA activity, MLC2 phos-
phorylation, and the increased expression of tight junction proteins represent important
features of HSP90 inhibition that are crucial as endothelial barrier protectants (Figure 9).
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Ras homolog family ember A (RhoA) actively maintains cadherin expression but when activated
is responsible of increased actomyosin contrac ility via cofili and myosin lig t chain 2 (MLC2).
Protein kinase B (AKT) and extracellular signal regulated kinase (ERK) are similarly involv d in
endothelial reorganization and injury. AUY-922, by inhibiting the sphorylated form of HSP90,
block actomyosin contractility and endothelial rearrangement. In addition, AUY-922 favors the
expression of cytoprotective p53 and HSP70. Finally, increasing the phosphorylated form of cofilin
promotes the expression of tight junction proteins, such as VE-cadherin and occludin.
hile we have already shown that HSP90 inhibitio could represent a new target
for antifibrotic therapy [13,27] in HCl-induced chro ic lung injury, this is the first report
that suggests HSP90 inhibition may be a promising approach for the treatment of HCl
acute endothelial injury. In fact, there are no FDA-approved drugs for the treatment of
HCl-toxicity. This study, however, has limitations. The ECIS assay represents a useful but
simplified model of capillary permeability. The cells are seeded on electrodes and lack all
the cellular complexity that defines microvascular an tom . Still, this model could be of
use for future research regarding pathological conditions with persistent acidosis, usually
observed in the critically ill (e.g., diabetic ketoacidosis, sepsis, respiratory failure) and
characterized by high morbidity and mortality.
5. Conclusions
Hydrochloric cid (HCl) is a toxic chemical whose exposure is r lated to severe,
potentially lethal, acute and chronic toxicity. Here we show that HCl provokes human
lung microvascular endothelial cell barrier dysfunction via the activation of ERK and AKT
and the consequent activation of cytoskeletal proteins. AUY-922, a third-generation HSP90
inhibitor, prevented and restored HCl-induced endothelial barrier hyperpermeability by
modulating ERK and AKT phosphoryl tion, preventing increase in RhoA, and promoting
the expression of VE-Cadherin. The inhibition of HSP90 represents a promising new
therapeutical target for HCl-induced acute lung injury and endothelial dysfunction.
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